ArticleMolecules (Basel, Switzerland)2022

Bis-Cinnamamide Derivatives as APE/Ref-1 Inhibitors for the Treatment of Human Melanoma.

Razan Alhazmi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.